82 Views | 28 Downloads
Todd E. Golde, 1275 Center Drive, Gainesville, Florida 32610, USA. Phone: 352.273.9456; Email: tgolde@ufl.edu
Nilüfer Ertekin-Taner: 4500 San Pablo Rd. S #378, Jacksonville, Florida 32224, USA. Phone: 904.953.7103; Email: taner.nilufer@mayo.edu
TEG, NET, and MA conceived the idea. XW, MA, JSR, YM, and SRO performed quality control and analyses. NET, TEG, MA, CF, and NDP developed the study concept. TEG, XW, and NET wrote the manuscript. DWD provided tissue from the Mayo Clinic Brain Bank and neuropathologically characterized the Mayo brain samples. NTS and AIL generated the proteomics data. TN, KGM, MA, and MMC performed sample selection and library preparation. OI, FQTN, and CCGH performed qPCR experiments. MCC and MEM performed immunohistochemistry experiments. TEG, NET, SGY, and YWA supervised the analytical aspects of the project. NET and TEG provided funding, supervision, and direction for the whole study. All authors read and approved the final manuscript.
We are grateful for the participation of the patients and their families, without whom these studies would not have been possible. The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). The Mayo RNA-Seq study was led by Nilüfer Ertekin-Taner (Mayo Clinic, Jacksonville, Florida, as part of the multi-PI (MPI) U01 AG046139 (MPIs Golde, Ertekin-Taner, Younkin, and Price). Samples were obtained from the Mayo Clinic Brain Bank. Data collection was supported through funding from the National Institute on Aging (NIA), NIH (P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, and R01 AG003949); the National Institute of Neurological Disorders and Stroke (NINDS), NIH (R01 NS080820); the CurePSP Foundation; and the Mayo Foundation. Study data included samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona, USA. The Brain and Body Donation Program is supported by the NINDS (U24 NS072026, National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders); the NIA (P30 AG19610, Arizona Alzheimer’s Disease Core Center); the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center); the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001, to the Arizona Parkinson’s Disease Consortium); and the Michael J. Fox Foundation for Parkinson’s Research.
The authors have declared that no conflict of interest exists.
© 2022 Wang et al.